337 related articles for article (PubMed ID: 37623252)
1. Recent Advances in Molecular Mechanisms of Nucleoside Antivirals.
Kamzeeva PN; Aralov AV; Alferova VA; Korshun VA
Curr Issues Mol Biol; 2023 Aug; 45(8):6851-6879. PubMed ID: 37623252
[TBL] [Abstract][Full Text] [Related]
2. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
3. Drug Repurposing Approaches for the Treatment of Influenza Viral Infection: Reviving Old Drugs to Fight Against a Long-Lived Enemy.
Pizzorno A; Padey B; Terrier O; Rosa-Calatrava M
Front Immunol; 2019; 10():531. PubMed ID: 30941148
[TBL] [Abstract][Full Text] [Related]
4. Advanced Prodrug Strategies in Nucleoside and Non-Nucleoside Antiviral Agents: A Review of the Recent Five Years.
Sinokrot H; Smerat T; Najjar A; Karaman R
Molecules; 2017 Oct; 22(10):. PubMed ID: 29035325
[No Abstract] [Full Text] [Related]
5. A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase.
Khan S; Attar F; Bloukh SH; Sharifi M; Nabi F; Bai Q; Khan RH; Falahati M
Int J Biol Macromol; 2021 Jun; 181():605-611. PubMed ID: 33766591
[TBL] [Abstract][Full Text] [Related]
6. Repurposing of nucleoside- and nucleobase-derivative drugs as antibiotics and biofilm inhibitors.
Yssel AEJ; Vanderleyden J; Steenackers HP
J Antimicrob Chemother; 2017 Aug; 72(8):2156-2170. PubMed ID: 28575223
[TBL] [Abstract][Full Text] [Related]
7. Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy.
Li J; Liu S; Shi J; Wang X; Xue Y; Zhu HJ
ACS Pharmacol Transl Sci; 2021 Apr; 4(2):870-887. PubMed ID: 33855276
[TBL] [Abstract][Full Text] [Related]
8. Broad-Spectrum Antiviral Strategies and Nucleoside Analogues.
Geraghty RJ; Aliota MT; Bonnac LF
Viruses; 2021 Apr; 13(4):. PubMed ID: 33924302
[TBL] [Abstract][Full Text] [Related]
9. Strategy, Progress, and Challenges of Drug Repurposing for Efficient Antiviral Discovery.
Li X; Peng T
Front Pharmacol; 2021; 12():660710. PubMed ID: 34017257
[TBL] [Abstract][Full Text] [Related]
10. Broad-Spectrum Antiviral Activity of 3'-Deoxy-3'-Fluoroadenosine against Emerging Flaviviruses.
Eyer L; Svoboda P; Balvan J; Vičar T; Raudenská M; Štefánik M; Haviernik J; Huvarová I; Straková P; Rudolf I; Hubálek Z; Seley-Radtke K; de Clercq E; Růžek D
Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33229424
[TBL] [Abstract][Full Text] [Related]
11. Repurposing Antifungals for Host-Directed Antiviral Therapy?
Schloer S; Goretzko J; Rescher U
Pharmaceuticals (Basel); 2022 Feb; 15(2):. PubMed ID: 35215323
[TBL] [Abstract][Full Text] [Related]
12. [New strategies for the development of antiviral molecules].
Castel G; Tordo N
Rev Francoph Lab; 2009 Dec; 2009(417):91-100. PubMed ID: 32288807
[TBL] [Abstract][Full Text] [Related]
13. [Antiviral and Antimicrobial Nucleoside Derivatives: Structural Features and Mechanisms of Action].
Zenchenko AA; Drenichev MS; Ilyicheva IA; Mikhailov SN
Mol Biol (Mosk); 2021; 55(6):897-926. PubMed ID: 34837696
[TBL] [Abstract][Full Text] [Related]
14. Targeting viral genome synthesis as broad-spectrum approach against RNA virus infections.
Huchting J
Antivir Chem Chemother; 2020; 28():2040206620976786. PubMed ID: 33297724
[TBL] [Abstract][Full Text] [Related]
15. Virus-Host Interactions: New Insights and Advances in Drug Development Against Viral Pathogens.
Prasad M; Ranjan K; Brar B; Shah I; Lalmbe U; Manimegalai J; Vashisht B; Gaury M; Kumar P; Khurana SK; Prasad G; Rawat J; Yadav V; Kumar S; Rao R
Curr Drug Metab; 2017; 18(10):942-970. PubMed ID: 28952435
[TBL] [Abstract][Full Text] [Related]
16. Escape of Tick-Borne Flavivirus from 2'-
Eyer L; Kondo H; Zouharova D; Hirano M; Valdés JJ; Muto M; Kastl T; Kobayashi S; Haviernik J; Igarashi M; Kariwa H; Vaculovicova M; Cerny J; Kizek R; Kröger A; Lienenklaus S; Dejmek M; Nencka R; Palus M; Salat J; De Clercq E; Yoshii K; Ruzek D
J Virol; 2017 Nov; 91(21):. PubMed ID: 28814513
[TBL] [Abstract][Full Text] [Related]
17. Resistance to a Nucleoside Analog Antiviral Drug from More Rapid Extension of Drug-Containing Primers.
Chen H; Lawler JL; Filman DJ; Hogle JM; Coen DM
mBio; 2021 Feb; 12(1):. PubMed ID: 33563814
[TBL] [Abstract][Full Text] [Related]
18. Kill or corrupt: Mechanisms of action and drug-resistance of nucleotide analogues against SARS-CoV-2.
Shannon A; Canard B
Antiviral Res; 2023 Feb; 210():105501. PubMed ID: 36567022
[TBL] [Abstract][Full Text] [Related]
19. A review: Mechanism of action of antiviral drugs.
Kausar S; Said Khan F; Ishaq Mujeeb Ur Rehman M; Akram M; Riaz M; Rasool G; Hamid Khan A; Saleem I; Shamim S; Malik A
Int J Immunopathol Pharmacol; 2021; 35():20587384211002621. PubMed ID: 33726557
[TBL] [Abstract][Full Text] [Related]
20. Drug Repurposing for Viral Infectious Diseases: How Far Are We?
Mercorelli B; Palù G; Loregian A
Trends Microbiol; 2018 Oct; 26(10):865-876. PubMed ID: 29759926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
